AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZeneca’s Imfinzi ...

Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and ...

AstraZeneca's Imfinzi Approved In EU For Muscle-Invasive Bladder Cancer July 04, 2025 — 02:13 am EDT Written by RTTNews.com for RTTNews -> (RTTNews) - British drug major AstraZeneca Plc.

AstraZeneca PLC (NASDAQ: AZN) announced Monday that the European Commission has approved Imfinzi (durvalumab) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC).

(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone. The ...

AstraZeneca (LON: AZN) PLC (NASDAQ: AZN) announced Monday that the European Commission has approved Imfinzi (durvalumab) for the treatment of adult patients with resectable muscle-invasive bladder ...

Imfinzi (durvalumab), which is used to treat some cancers, can cause side effects. Learn more about Imfinzi's side effects, such as cough, rash, and hair loss.

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from ...

Imfinzi, which is used to treat some types of cancer, can cause side effects. Learn about common, mild, and serious side effects and how to manage them.

AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).